NCT03224260 is a Phase 1 clinical trial of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03224260?

NCT03224260 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03224260?

Interventions in NCT03224260: BMS-986177, Matched Placebo.

What condition does NCT03224260 study?

NCT03224260 studies Thrombosis.

Is NCT03224260 still recruiting?

NCT03224260 is currently completed. Last updated 1 June 2018.

Last reviewed 2018-06-01 · How we verify

NCT03224260

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Completed Phase 1 Last updated 1 June 2018

What this trial tests

Phase 1 trial testing BMS-986177 in Thrombosis in 33 participants. Completed in 7 November 2017.

Timeline

28 June 2017

Primary endpoint
7 November 2017

7 November 2017

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	other
Enrollment	33
Start date	28 June 2017
Primary completion	7 November 2017
Estimated completion	7 November 2017
Sites	1 location across United States

Drugs / interventions tested

BMS-986177 — full drug profile →
Matched Placebo — full drug profile →

Conditions studied

Thrombosis — all drugs for Thrombosis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 55, any sex, with Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Plasma contact factors as therapeutic targets.
Tillman BF, Gruber A, McCarty OJT, Gailani D. · · 2018 · cited 52× · PMID 30075986 · DOI 10.1016/j.blre.2018.04.001
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
Perera V, Wang Z, Lubin S, Ueno T, et al · · 2022 · cited 14× · PMID 35338177 · DOI 10.1038/s41598-022-08768-y
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.
Xia Y, Hu Y, Tang L. · · 2023 · cited 12× · PMID 37375813 · DOI 10.3390/ph16060866

Verify or expand the search:

Other trials of BMS-986177

Trials testing the same drug.

NCT03939702 — Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants · Phase 1 · completed
NCT03766581 — A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel · Phase 2 · completed
NCT03698513 — A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects · Phase 1 · completed
NCT02982707 — Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants · Phase 1 · completed
NCT03362437 — Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants · Phase 1 · completed

Other recruiting trials for Thrombosis

Currently open trials in the same condition.

NCT07137429 — Platelet Volunteers, Longitudinal and Multi-omic Study · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06993740 — Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient · NA · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
NCT06370273 — Thromboprophylaxis in Lower Limb Immobilisation · Phase 3 · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03224260 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 1 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03224260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing